SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Pump.fun

$PUMP is trending amid community enthusiasm and the popular 'WAGMI' (We're All Gonna Make It) mantra, with many highlighting its potential within the Solana ecosystem. Discussions revolve around its strong community, recognizable branding, and the belief that it's coded for significant growth. The community views $PUMP as more than just a ticker, but a mission statement.

Solana is a highly functional open source project that banks on blockchain technology’s permissionless nature to provide decentralized finance (DeFi) solutions. It is a layer 1 network that offers fast speeds and affordable costs. While the idea and initial work on the project began in 2017, Solana was officially launched in March 2020 by the Solana Foundation with headquarters in Geneva, Switzerland.

Solana

Solana is trending as community members discuss potential breakouts and accumulation zones for related tokens like $SMAS and $WAGMI. Some traders are watching key resistance levels, while others express optimism about Solana's future growth and potential ETF approval. There's also discussion around meme coins built on Solana, like $UPDOG and $SOLYCAT.

Trump For President

The Trump Crypto token is trending amidst community discussions around its performance and potential connection to political events. Some traders are expressing concerns about its volatility, while others are speculating on future growth tied to Trump's political activity; overall sentiment appears mixed, with some users calling it a 'scam coin'.

WorldFinancial

WLFI is trending as community members discuss its connection to $TRUMP and potential for real-world asset tokenization. Speculation is fueled by potential partnerships and product launches like the USD1 stablecoin and a debit card. Community chatter also focuses on market manipulation, short squeezes, and the impact of regulatory clarity.

Avidity Biosciences, Inc. engages in the development of a new class of oligonucleotide-based therapies called Antibody Oligonucleotide Conjugates (AOC). It utilizes its AOC platform to design, engineer, and develop therapeutics that combine the tissue selectivity of monoclonal antibodies and the precision of oligonucleotide-based therapies in order to access previously undruggable tissue and cell types and more effectively target underlying genetic drivers of diseases. The company was founded by Troy E. Wilson, Kent Hawryluk, Mark E. Davis, and Francis Patrick McCormick on November 13, 2012 and is headquartered in San Diego, CA.

Avidity Biosciences Inc

Avidity Biosciences ($RNA) is trending amid rumors of a potential acquisition by Novartis, driving significant community discussion and a surge in stock price. Investors are closely watching upcoming conferences and data readouts, speculating on the likelihood of a buyout offer and its potential premium. The focus remains on Avidity's pipeline and its potential impact on the rare neuromuscular disease treatment landscape.

Shibmas was launched on the 9th Of December. The project is a meme token and gives homage to Shiba Inu the token. The token is a playful character who is bringing the Christmas spirit to token holders all around the world. We plan on getting many listings on various exchanges in the coming days. We have over 1000 holders in 24 hours and we aim on getting over 10000 holders within the next week and in the run up to Christmas

Shibmas

Shibmas ($SMAS) is gaining attention, with community members noting its trending status and "moon vibes." Talk centers on its availability on Phantom Wallet and potential breakout, as well as its connection to the Shiba Inu ($SHIB) community. Traders are closely watching price action and volume for signals.

Just a dead guy

$DEADGUY is trending as the community promotes the coin and shares the contract address. Social media mentions are up as the coin gains holders and climbs in wallet rankings. Discussion includes speculation that $DEADGUY could surpass other similar coins.

Mid-America Apartment Communities, Inc. is a real estate investment trust, which engages in the operation, acquisition, and development of apartment communities. It operates through the Same Store and Non-Same Store segments. The Same Store Communities segment represents those apartment communities that have been owned and stabilized for at least 12 months as of the first day of the calendar year. The Non-Same Store segment includes recent acquisitions, communities in development or lease-up. The company was founded in 1994 and is headquartered in Germantown, TN.

Mid-America Apartment Communities, Inc.

Mid-America Apartment Communities ($MAA) is trending amid rating updates from analysts, with community members actively discussing target prices and potential ROI on call options. Discussions also highlight multifamily REIT resilience and the impact of interest rate fluctuations. Some are weighing the company's Sunbelt exposure against concerns about rental supply and rising interest expenses.

Performance Food Group Co. engages in the market and distribution of food products. It operates through the following segments: Foodservice, Convenience, and Specialty. The Foodservice segment delivers food and food-related products to independent restaurants, chain restaurants, and other institutional food-away-from-home locations. The Convenience segment consists of a range of products, marketing programs and technology solutions to locations in the United States and Canada. The Specialty segment offers candy, snack, and beverage to customers in the vending, office coffee services, theater, retail, and other channels. The company was founded by James Capers in 1885 and is headquartered in Richmond, VA.

Performance Food Group Company

Performance Food Group is trending due to reports of takeover interest from US Foods, sparking community discussion about a potential deal. Upgraded ratings from analysts at Barclays and Bernstein, along with call option alerts, are also contributing to the increased attention. Investors are also reviewing the company's recent earnings, which beat expectations, and 10-K risk factors.

Sagimet Biosciences, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of novel therapeutics for the treatment of infectious diseases. Its lead drug candidate, denifanstat, is an oral, once-daily pill and selective fatty acid synthase (FASN) inhibitor in development for the treatment of nonalcoholic steatohepatitis (NASH). The company was founded by Urs F. Greber, Ari Helenius, and Lucas Pelkmans on December 19, 2006 and is headquartered in San Mateo, CA.

Sagimet Biosciences Inc - Ordinary Shares - Series A

Sagimet Biosciences Inc

Sagimet Biosciences ($SGMT) is trending due to positive Phase 3 trial data for its acne treatment, denifanstat, potentially offering a new Accutane alternative with fewer side effects. The community is buzzing about its market potential, especially in China, and speculating about a possible buyout from larger skincare companies. Some analysts see the stock as undervalued, citing its market cap and opportunities in both the acne and MASH markets.

statis crypto Watchlist

Bitcoin

Ethereum

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Avidity Biosciences Enters into Agreement to be Acquired by Novartis AG

Avidity Biosciences Enters into Agreement to be Acquired by Novartis AG Avidity Biosciences Enters into Agreement to be Acquired by Novartis AG PR Newswire SAN DIEGO, Oct. 26, 2025 Novartis to...

Novartis is in talks to buy U.S. biotech firm Avidity Biosciences for more than $70 a share, Bloomberg News reports

Swiss pharmaceutical giant Novartis is nearing a deal to buy biotechnology company Avidity Biosciences for more than $70 a share, Bloomberg News reported...

Avidity Biosciences to Participate in Upcoming Investor Conference

Avidity Biosciences to Participate in Upcoming Investor Conference Avidity Biosciences to Participate in Upcoming Investor Conference PR Newswire SAN DIEGO, Oct. 16, 2025 SAN DIEGO, Oct. 16, 2025...

Avidity Biosciences Announces Positive Pre-BLA Meeting with U.S. FDA for del-zota in DMD44 with a Submission Planned for Q1 2026

Avidity Biosciences Announces Positive Pre-BLA Meeting with U.S. FDA for del-zota in DMD44 with a Submission Planned for Q1 2026 Avidity Biosciences Announces Positive Pre-BLA Meeting with U.S. FDA...

Shares of Avidity Biosciences, Inc. (RNA) fell 20% in the pre-market session on Thursday after the company announced that it intends to offer and sell $500 million of shares of its common stock in an underwritten public offering.The company <a target="_blank" rel="noopener noreferrer nofollow" href="https://www.prnewswire.com/news-releases/avidity-biosciences-announces-proposed-public-offering-of-common-stock-302553124.html">stated</a> that it intends to grant the underwriters an option to purchase up to an additional $75 million of shares, while adding that there can be no assurance as to whether or when the offering may be completed.The proceeds of the offering are expected to advance the development of the company’s three late-stage clinical programs, help build appropriate commercial inventory levels to support multiple potential launches, and expand its commercial infrastructure. The company also intends to progress research and development associated with its Antibody Oligonucleotide Conjugates platform and use the proceeds for working capital and general corporate purposes.Avidity had cash, cash equivalents, and marketable securities totaling approximately $1.2 billion as of June 30. It had stated in August that it expects to have sufficient funds for its operations through mid-2027.On Stocktwits, retail sentiment around <a href="https://stocktwits.com/symbol/RNA">RNA stock</a> rose from ‘neutral’ to ‘bullish’ over the past 24 hours, while message volume rose from ‘normal’ to ‘extremely high’ levels.<figure class="image"><img style="aspect-ratio:1360/122;" src="https://news.stocktwits-cdn.com/Screenshot_2025_09_11_at_7_16_45_AM_png_8af84254fb.webp" alt="RNA's Sentiment Meter and Message Volume as of 7:17 a.m. ET on Sept. 11, 2025 | Source: Stocktwits" width="1360" height="122"><figcaption>RNA's Sentiment Meter and Message Volume as of 7:17 a.m. ET on Sept. 11, 2025 | Source: Stocktwits</figcaption></figure>A Stocktwits user opined that Avidity stock has a good chance of hitting $100 in a year.<stembedurl>https://stocktwits.com/dgbio/message/628258214</stembedurl>The Financial Times <a href="https://stocktwits.com/news-articles/markets/equity/novartis-reportedly-eyeing-to-acquire-avidity-biosciences/chrSPptRd5k">reported</a> last month that Novartis made a takeover approach for Avidity, adding that the discussions were at an early stage and might not result in a deal.Avidity has three programs under development for three distinct rare diseases affecting the muscles: myotonic dystrophy type 1 (DM1), facioscapulohumeral muscular dystrophy (FSHD), and Duchenne Muscular Dystrophy (DMD). Bank of America raised its price target on Avidity to $56 from $54 on Thursday, while maintaining a ‘Buy’ rating on the shares. The firm pinned the price target hike on recent study results, which showed that treatment with Avidity’s Del-zota reversed disease progression in patients with DMD.RNA stock is up by about 60% this year and by about 14% over the past 12 months.&nbsp;Read also:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/dow-futures-edge-higher-ahead-of-cpi-report/chwN03BRdv4">Dow Futures Edge Higher As Wall Street Awaits Consumer Inflation Data: ORCL, OPEN, KLAR, ADBE Among Stocks To Watch</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Why Is Avidity Biosciences Stock Down 20% Pre-market Today?

Avidity said on Thursday that it intends to offer and sell $500 million of shares of its common stock in an underwritten public offering.

Equity

Avidity said on Thursday that it intends to offer and sell $500 million of shares of its common stock in an underwritten public offering.


RNA Stock Moves More Than 30% in a Week: What's Driving This Rally?

Avidity Biosciences surges 36% on reports that Novartis may eye a deal, with talks said to be early and interest from other suitors possible.

Clene Inc. (CLNN) Reports Q2 Loss, Misses Revenue Estimates

Clene (CLNN) delivered earnings and revenue surprises of -59.18% and -73.00%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?

Mersana Therapeutics, Inc. (MRSN) Reports Q2 Loss, Lags Revenue Estimates

Mersana Therapeutics (MRSN) delivered earnings and revenue surprises of -8.80% and -58.90%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?

Fate Therapeutics (FATE) Reports Q2 Loss, Beats Revenue Estimates

Fate Therapeutics (FATE) delivered earnings and revenue surprises of +17.14% and +190.70%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?

Iovance Biotherapeutics (IOVA) Reports Q2 Loss, Lags Revenue Estimates

Iovance Biotherapeutics (IOVA) delivered earnings and revenue surprises of -13.79% and -9.64%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?

Cut 25 bps

Cut 50+ bps

No change

What will the Fed decide at its October meeting? Polymarket gives a 92% chance of a 25 bps cut. 
 
*Powered by Polymarket

RNA
Avidity Biosciences Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest RNA News

RNAAvidity Biosciences Inc